OP29 THE IMPACT OF INSULIN TREATMENT IN COMBINATION WITH ORAL ANTI-DIABETES DRUGS IN REAL-WORLD SETTING IN CHINA: RESULTS FROM SEAS STUDY (SCILIN EFFICACY AND SAFETY OBSERVATIONAL STUDY)

of fasting triglyceride as compared with nateglinide (P = 0.005). As to postprandial lipid profiles, significantly lower triglyceride levels at both 30min (D=−0.34±0.46mmol/L, P< 0.001) and 120min (D=−0.37±0.72mmol/L, P = 0.002) after meal were observed after acarbose treatment. In contrast, nateglinide treatment decreased the postprandial triglyceride at 30min (D=−0.25±0.73mmol/L, P = 0.029) but not at 120min (D=−0.19±0.89mmol/L, P =0.169). The alterations of total cholesterol, high density lipoprotein and low density lipoprotein were not significant after either nateglinide or acarbose treatment. The nateglinide and acarbose treatmentrelated changes in postprandial TG, both at 30 min and 120 min, were significantly correlated with the changes in fasting TG. In addition, the improvement in TG at postprandial 30min was shown to be correlated to an increased insulin response observed at that same stage (r =−0.34, p = 0.028). Conclusion: The current study showed that a 2-week treatment course of either nateglinide or acarbose can significantly reduce both fasting and postprandial TG levels. Acarbose provided more robust TG-lowering, however, and may represent the more superior treatment option between these two oral anti-diabetic agents. Studieswith larger sample size and longer treatment course and follow-up time are needed to confirm these findings.